Synta Pharmaceuticals Corp. clinical trials

Acquired by Madrigal Pharmaceuticals, Inc., Jul 22, 2016 · source ↗

The registry lists 25 studies whose lead sponsor is Synta Pharmaceuticals Corp.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 1, 2016.

Studies

Recruiting first, then most recently updated. Showing 25 of 25. All Madrigal Pharmaceuticals, Inc. studies →

• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCTerminatedNCT01798485Phase 3

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)CompletedNCT01039519Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung CancerTerminatedNCT01348126Phase 2/3

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast CancerCompletedNCT01677455Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01562015Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01031225Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid TumorsCompletedNCT01183364Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative DisordersCompletedNCT00858572Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-9090, Administered Once-Weekly in Patients With Solid TumorsCompletedNCT00687934Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-9090, Administered Twice-Weekly in Patients With Solid TumorsStatus unknownNCT00688116Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-4783 and Paclitaxel for Treatment of Solid TumorsCompletedNCT00088114Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-4783/Paclitaxel or Paclitaxel Alone in MelanomaCompletedNCT00084214Phase 1/2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in MelanomaTerminatedNCT00522834Phase 3

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue OutcomesCompletedNCT00642629Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownNCT01280786Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate CancerCompletedNCT00808418Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT00276913Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid TumorsSuspendedNCT00827203Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00138840Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid TumorsCompletedNCT00088101Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00234741Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)CompletedNCT00088088Phase 1/2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue SarcomasCompletedNCT00087997Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-5326 in Crohn's Disease PatientsCompletedNCT00088062Phase 1/2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.